

Eton CARES helps make it easy for your patients to get started and stay on treatment

Eligible, commercially insured patients pay as little as:

\$0 per month*

*Restrictions, limitations, and/or eligibility requirements may apply.



We are committed to increasing the availability of individualized treatment with Alkindi Sprinkle® (hydrocortisone) oral granules for patients through the Eton CARES program

- When you submit your prescription, patients are automatically enrolled in Eton CARES for a benefits investigation, hands-on support, and access to financial assistance
- After receiving your prescription, the Nurse Ambassador will call the patient within 3 days to explain next steps. The patient will also receive regular calls from the Nurse Ambassador to answer any questions about the medication
- Once the benefits investigation is complete, the Anovo Pharmacist will call to arrange delivery. The first delivery will arrive as soon as 24 hours from the time the prescription is submitted, but typically within 3 to 7 days[‡]

[†]Data from November 2020–December 2022 of insured patients. Insured patient claims may require a prior authorization or an appeal.

[‡]For newborns awaiting hospital discharge, medication may be delivered as soon as 24 hours. Typical delivery is 3–7 days.

[97%]

of prescriptions were successfully approved by insurance[†]

Anovo® Specialty Pharmacy can provide support for prior authorizations and appeals, if requested.

INDICATION

ALKINDI SPRINKLE is a corticosteroid indicated for replacement therapy in pediatric patients with adrenocortical insufficiency.

IMPORTANT SAFETY INFORMATION

Contraindication

Hypersensitivity to hydrocortisone or any of the ingredients in ALKINDI SPRINKLE.

Warnings and Precautions

- **Adrenal Crisis:** Undertreatment or sudden discontinuation of therapy may lead to symptoms of adrenal insufficiency, adrenal crisis, and death. Adrenal crisis may also be induced by stressor events, such as infections or surgery. Monitor patients closely when switching from other forms of hydrocortisone to ALKINDI SPRINKLE. Instruct patients and/or caregivers to contact their healthcare provider if the full dose of ALKINDI SPRINKLE is not administered, as a repeat dose may be required. Increase the dose during periods of stress. Switch patients who are vomiting, severely ill, or unable to take oral medications to parenteral corticosteroid formulations.

[Click here](#) for additional Important Safety Information.
[Click here](#) for full Prescribing Information.



With the Quick Start program,
your patients can begin treatment
in as soon as 24 hours*

Alkindi Sprinkle® within
24 hours
through the
Quick Start Program*

Quick Start program*†

- A 30-day supply of treatment can be delivered in as soon as 24 hours at no cost

Bridge program†

- Prior to completion of the benefits investigation, continuing treatment is provided until prior authorization is approved, or the patient is transitioned to the Patient Assistance Program‡



The Pharmacist will call within 3 days to get started

- The patient will receive calls from the Pharmacist to review key information about the medicine and arrange delivery. The Pharmacist will then continue to call 7 days prior to each refill date
- The Nurse Ambassador will also call the patient periodically to answer questions about the medication and address any questions about administration

Important: Tell patients to expect a call from Anovo at this number: **(901) 201-5470** and to save it on their phone. Product cannot be shipped until Anovo arranges delivery with the patient.

Quick Start*†

30-day supply of
treatment delivered
as soon as 24 hours*

Bridge Program*†

Continued treatment is provided until insurance determination is made‡

*For newborns awaiting hospital discharge, medication may be delivered in as soon as 24 hours. Typical delivery is 3-7 days.

†Restrictions, limitations, and/or eligibility requirements may apply.

‡Anovo will work with the HCP to obtain insurance coverage. If insurance is denied, the patient may apply to the Patient Assistance Program.

[Click here](#) for full Important Safety Information.
[Click here](#) for full Prescribing Information.



INDICATION AND IMPORTANT SAFETY INFORMATION

Contraindication

Hypersensitivity to hydrocortisone or any of the ingredients in ALKINDI SPRINKLE.

Warnings and Precautions

- **Adrenal Crisis:** Undertreatment or sudden discontinuation of therapy may lead to symptoms of adrenal insufficiency, adrenal crisis, and death. Adrenal crisis may also be induced by stressor events, such as infections or surgery. Monitor patients closely when switching from other forms of hydrocortisone to ALKINDI SPRINKLE. Instruct patients and/or caregivers to contact their healthcare provider if the full dose of ALKINDI SPRINKLE is not administered, as a repeat dose may be required. Increase the dose during periods of stress. Switch patients who are vomiting, severely ill, or unable to take oral medications to parenteral corticosteroid formulations.
- **Infections:** Excessive doses may increase the risks of new infections or exacerbation of latent infections with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic infections. Monitor patients for signs and symptoms of infections. Treat all infections seriously, and initiate stress dosing of steroids early.
- **Growth Retardation:** Long-term use in excessive doses may cause growth retardation. Use the minimum dosage of ALKINDI SPRINKLE to achieve desired clinical response and monitor the patient's growth.
- **Cushing's Syndrome Due to Use of Excessive Doses of Corticosteroids:** Prolonged use with supraphysiologic doses may cause Cushing's syndrome. Monitor patients for signs and symptoms of Cushing's syndrome every 6 months; pediatric patients under one year of age may require more frequent monitoring.
- **Decrease in Bone Mineral Density:** Corticosteroids decrease bone formation and increase bone resorption, which may lead to inhibition of bone growth and development of osteoporosis. Use the minimum dosage of ALKINDI SPRINKLE to achieve desired clinical response.
- **Psychiatric Adverse Reactions:** Use may be associated with severe psychiatric adverse reactions, such as euphoria, mania, psychosis with hallucinations and delirium, or depression. Symptoms typically emerge within a few days or weeks of starting the treatment. Most reactions resolve after either dose reduction or withdrawal, although specific treatment may be necessary. Monitor patients for behavioral and mood disturbances during treatment. Instruct caregivers and/or patients to seek medical advice if psychiatric symptoms develop.
- **Ophthalmic Adverse Reactions:** Cataracts, glaucoma, and central serous chorioretinopathy have been reported with prolonged use of high doses. Monitor patients for blurred vision or other visual disturbances, and if they occur, refer them to an ophthalmologist.
- **Gastrointestinal Adverse Reactions:** There is an increased risk of gastrointestinal perforation in patients with certain gastrointestinal disorders. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked in patients receiving corticosteroids. Corticosteroids should be used with caution if there is a probability of impending perforation, abscess, or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; and active or latent peptic ulcer.
Concurrent administration of corticosteroids with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal adverse reactions. Monitor patients receiving corticosteroids and concomitant NSAIDs for gastrointestinal adverse reactions.

Adverse Reactions

Common adverse reactions for corticosteroids include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite, and weight gain.

To report a suspected adverse event related to ALKINDI SPRINKLE, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at <http://www.fda.gov/MedWatch> or call 1-800-FDA-1088.

INDICATION

ALKINDI SPRINKLE is a corticosteroid indicated for replacement therapy in pediatric patients with adrenocortical insufficiency.

[Click here for full Prescribing Information.](#)

Your prescriptions for ALKINDI SPRINKLE® (hydrocortisone) oral granules must be submitted to Anovo® Specialty Pharmacy



Fax the Referral Form to

1-855-813-2039

The referral form captures your prescription details and information for the benefits investigation process



e-Prescribe via your EMR

- Select **Anovo #5** for pharmacy
- Remove geographical radius in search criteria

Anovo will follow up for patient information required for the benefits investigation process



Call

1-833-343-2500

(M-F, 8 PM-5 PM CT)

If you provide sick-day doses, remember to include them in your prescription, so your patient can avoid an additional copay

If the Rx is submitted via EMR, enter the sick-day dosing information in the “Free Text” or “Instructions” section of the e-script

For questions regarding prescription fulfillment, please contact Anovo at

1-888-991-1330

Personalized support that puts the patient first



A DEDICATED ETON CARES TEAM

Knowledgeable and reliable professionals fully trained on ALKINDI SPRINKLE



Nurse Ambassadors

- Regular check-ins
- Answer questions



Pharmacists

- 24/7 support
- Refill reminders
- Shipment alerts



Insurance Specialists

- Benefits verification and appeal
- Prior authorization assistance

Copay support

Eton Cares can help eligible, commercially insured patients get their medication for as little as **\$0** per month*

Financial support

Patients who do not have insurance and who meet certain financial requirements may be eligible for additional financial support from a Patient Assistance Program*

*Restrictions, limitations, and/or eligibility requirements may apply. For patients who are not eligible for copay support or who need additional financial assistance, Eton Cares can help connect you with alternative forms of medication coverage or provide referrals to other possible sources of funding.

[Click here](#) for full Important Safety Information.

[Click here](#) for full Prescribing Information.

1. Data on file. Eton Pharmaceuticals, Inc. January 2023.